Medikine Presents Preliminary Results of a Single-Dose Phase 1 Healthy Subject Study of MDK-703, a Peptide-Based Mimetic of Interleukin-7 (IL-7)

Results presented at the Society for Immunotherapy of Cancer’s 37th Annual Meeting describe human data of a product candidate generated by Medikine’s proprietary PEPTIKINE™ platform in humans Intramuscular doses of MDK-703 studied were safe and well-tolerated in healthy subjects and had IL-7-like effects on immune cells in blood Additional preclinical data presented for MDK-1654, a … [Read more…]

eClinical Solutions’ Thought Leaders to Discuss the Future of Data Standards, Risk-Based Approaches, and Digital Trials at PHUSE EU Connect 2022, Medidata NEXT New York 2022 and More

Presentations and demonstrations will highlight how modern clinical data infrastructure and analytics platforms and optimized processes accelerate increasingly complex trials BOSTON–(BUSINESS WIRE)–eClinical Solutions, a global provider of digital clinical software and services, today announced that the company’s experts will be presenting a variety of sessions and demonstrations at PHUSE EU Connect 2022. Thought leaders Venu … [Read more…]

Aulos Bioscience Presents Initial Data From First-in-Human Phase 1/2 Clinical Trial of Computationally Designed Antibody AU-007 at 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Data show trend in decreasing Tregs, presenting unique profile among current IL-2 therapeutics Adding Phase 1/2 clinical trial sites in the U.S. following recent IND application clearance LARKSPUR, Calif.–(BUSINESS WIRE)–Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today presented early data from its Phase 1/2 … [Read more…]

Xencor Presents Early Clinical Data from Combination Study of Vudalimab and New Data from Multiple Preclinical-stage XmAb® Programs at the SITC Annual Meeting

MONROVIA, Calif.–(BUSINESS WIRE)–Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the presentation of data from the first patients in the Phase 2 combination study of vudalimab, a selective PD-1 x CTLA-4 XmAb® bispecific antibody, in patients with metastatic castration-resistant prostate cancer … [Read more…]

Seagen to Highlight New Research from its Diverse Pipeline of Targeted Cancer Therapy Candidates at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting

– Encouraging data from ongoing Phase 1 study of SGN-B6A illustrate commitment to pioneering novel first-in-class antibody-drug conjugates (ADCs) – BOTHELL, Wash.–(BUSINESS WIRE)–Seagen Inc. (Nasdaq: SGEN) today announced that data from the company’s diverse pipeline of targeted cancer therapy candidates will be presented at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting being held … [Read more…]

Triumvira Immunologics Demonstrates Strength of Preclinical Research Pipeline for Gastric and Colorectal Cancers in Three Posters at SITC 2022

AUSTIN, Texas & SOUTH SAN FRANCISCO, Calif. & HAMILTON, Ontario–(BUSINESS WIRE)–Triumvira Immunologics (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with cancer, today announced preclinical data for its investigational TAC-T cell therapies CLDN18.2-TAC T and GUCY2C-TAC T, and data … [Read more…]

IconOVir Announces New Preclinical Data Showcasing Best-in-Class Potential of ICVB-1042, its Lead Oncolytic Virus, at SITC 2022

— ICVB-1042 demonstrates selective replication, broad tropism and anti-tumor activity across multiple in vitro and in vivo models — — Proprietary Ad5/Ad34 mutation improves viral entry into target tumor cells, enhancing tropism — — On track to initiate Phase 1 trial in solid tumors in 1H 2023 — SAN DIEGO–(BUSINESS WIRE)–IconOVir Bio, Inc. (IconOVir), a … [Read more…]

Aimmune Therapeutics to Present Positive Results from Phase 3 POSEIDON Study of PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] in Peanut-Allergic Children Aged 1 to 3 Years

— Results Will be Presented for the First Time at the American College of Allergy, Asthma & Immunology (ACAAI) 2022 Annual Scientific Meeting — — 73.5% of Patients Treated with PALFORZIA Met the Primary Outcome at 12 Months Compared with 6.3% of Patients in the Placebo Arm — — 61% of Patients Treated with PALFORZIA … [Read more…]

VBI Vaccines Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Q3 marked a meaningful quarter for partnerships with a recently announced prophylactic hepatitis B commercialization collaboration in certain European countries with Valneva, and a clinical collaboration in glioblastoma with Agenus PreHevbrio™ [Hepatitis B Vaccine (Recombinant)], launched in the U.S. at the end of Q1 2022, is advancing through commercial stage gates required to enable broad … [Read more…]

Sprinter Health and Firefly Health Partner to Bring a New Model of Hybrid Care to Patients: Delivered in the Home and Powered by Technology for Scale

The partnership aims to improve access to care and strengthen patient engagement with Firefly primary care providers MENLO PARK, Calif.–(BUSINESS WIRE)–#healthcare—Sprinter Health, an on-demand mobile health and diagnostics company bringing personalized and affordable healthcare services to the home, today announced a partnership with Firefly Health, a health plan and virtual-first care innovator with a mission … [Read more…]